0 Ask Beta Account

Cyclic progesterone and spironolactone treatment for androgenic polycystic ovary syndrome

Dharani Kalidasan, Jerilynn C Prior

  • University of British Columbia, Vancouver, BC, Canada ROR
  • Vancouver Hospital and Health Sciences Centre ROR

http://isrctn.com/

DOI 10.1186/isrctn99343883

Abstract

No abstract available for this article.

Topics

PCOS > Treatment > Cyclic Progesterone TherapyPCOS > Treatment > Anti-Androgen TherapyRRM Methods > Hormonal Treatment > Progesterone Protocols
Prior JC cyclic progesterone PCOS treatment, spironolactone androgenic polycystic ovary syndrome, cyclic progesterone therapy hyperandrogenism PCOS, Prior JC spironolactone PCOS clinical trial, anti-androgen treatment polycystic ovary syndrome progesterone, PCOS randomized controlled trial progesterone spironolactone, restorative treatment androgenic PCOS ovulation, cyclic progestin therapy hirsutism acne PCOS, non-contraceptive hormonal treatment polycystic ovary syndrome, Prior Kalidasan PCOS progesterone protocol
DOI 10.1186/isrctn99343883 10.1186/isrctn99343883

Cite this article

Prior, J. C., & Kalidasan, D. (2021). Cyclic progesterone and spironolactone treatment for androgenic polycystic ovary syndrome. *http://isrctn.com/*. https://doi.org/10.1186/isrctn99343883

Related articles

"Phase II 6-month Cyclic Progesterone/Spironolactone pilot Therapy Trial in Polycystic Ovary Syndrome : pre-post, single-arm feasibility study"
Prior JC et al., 2021 Open Collections

Androgenic Polycystic Ovary Syndrome (PCOS) creates physical/emotional burdens in 4-20% of premenopausal women living with PCOS (WLWP) including: few menstruations per year, subfertility, hirsutism/ac...

PCOS > Treatment > Progesterone TherapyPCOS > Treatment > Anti-Androgen TherapyResearch Methodology > Study Design > Feasibility and Pilot Studies

MON-LB9 Cyclic Progesterone Therapy in Androgenic Polycystic Ovary Syndrome (PCOS) - Person-Related 6-Month Experience Changes
Shirin S et al., 2020 Open Access Journal of the Endocrine Society

Endometrial cancer1 and oligomenorrhea2 are common risks for women living with androgenic PCOS (WLWP); cyclic progesterone therapy could prevent both. Cyclic oral micronized progesterone therapy (Cycl...

PCOS > Treatment > Cyclic Progesterone TherapyReproductive Endocrinology > Progesterone > Luteal Phase ReplacementPCOS > Symptoms > Oligomenorrhea Management

MON-LB010 Cyclic Progesterone Therapy for Androgenic Polycystic Ovary Syndrome (PCOS) - A Systematic Review of the Literature
Shirin S et al., 2020 Open Access Journal of the Endocrine Society

Women living with androgenic PCOS (WLWP) experience unpredictable oligomenorrhea1 and are at increased risk for endometrial cancer2. Oral micronized progesterone (OMP) given cyclically (14 days/cycle ...

PCOS > Treatment > Cyclic Progesterone TherapyResearch Methodology > Systematic Review > Literature SearchPCOS > Pathophysiology > Neuroendocrine Mechanisms